CLINICAL TRIALS PROFILE FOR VANCOMYCIN

505(b)(2) Clinical Trials for vancomycin

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT01162733 ↗	Loading Vancomycin Doses in the Emergency Department	Completed	Christiana Care Health Services	N/A	2010-07-01	In 2008, our ED administered an average of 245 doses of vancomycin per month. Currently there is no consistency in the ED practice in regards to vancomycin dosing. In 2009, the IDSA put forth new recommendations for vancomycin dosing in order to achieve therapeutic levels more rapidly. It has been hypothesized that if therapeutic levels are reached more rapidly then patients will in turn have better clinical outcomes and that the development of resistant organisms will be decreased. Methicillin resistant Staphylococcus aureus (MRSA) has emerged as one of the most deadly pathogens that are currently plaguing our patient population. Vancomycin is one of only a few antibiotics that are effective for treating MRSA. It is imperative that the ED physicians consistently and correctly dose vancomycin in order to give the patients the best chance to fight infection while helping to prevent further resistance in this already highly resistant organism. It is believed this study will reveal that the new dosing recommendations by the IDSA will lead to the achievement of therapeutic levels more rapidly. This information will in turn help to convince ED physicians that a change in current clinical practice is warranted and ultimately lead to better clinically outcomes for the patients.
New Dosage	NCT01734694 ↗	Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients	Terminated	Henry Ford Health System	Phase 4	2011-10-01	For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various reasons. Recently, VIN has reemerged as a clinical concern. This may be due to various reasons, including new dosing recommendations as well as an increased prevalence of risk factors associated with vancomycin induced nephrotoxicity. This study aims to evaluate a strategy which attempts to reduce kidney damage from vancomycin use.
OTC	NCT04674839 ↗	The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals	Completed	Microbio Co Ltd	N/A	2019-10-18	MicrSoy-20 (MS-20), a fermented soymilk product, has been approved as an Over the counter (OTC) drug in 2011. The therapeutic effect of MS-20 is to ameliorate symptoms such as fatigue and loss of appetite caused by cancer chemotherapy. Animal study revealed orally administration of MS-20 daily for 4 weeks altered the gut microbiota composition in mice. In addition, MS-20 could activate dendritic cell and improve immunotherapy response rate. Thus, it was hypothesis that MS-20 improves host immune activity thus ameliorate fatigue and increase weight is through alteration the gut microbiota composition. In this study, the ability of MS-20 in modulating gut microbiota and the subset of microbiome to be altered by MS-20 was investigated.

All Clinical Trials for vancomycin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003805 ↗	Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1997-11-01	RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or Hodgkin's disease.
NCT00034294 ↗	A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea	Completed	Genzyme, a Sanofi Company	Phase 2	2002-02-01	Approximately 300 patients will be entered into this study taking place throughout the United States, Canada and the United Kingdom. This study aims to determine if an investigational drug is safe and effective for treating the symptoms of C. difficile-associated diarrhea and lowering the risk of repeat episodes of diarrhea. The investigational drug will be evaluated in comparison to current standard antibiotic treatment, so all patients will receive active medication. All study-related care is provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation is approximately 10 weeks.
NCT00035425 ↗	Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection	Completed	Pfizer	Phase 3	2001-11-01	This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).
NCT00035854 ↗	New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)	Completed	Pfizer	Phase 3	2002-02-01	This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)
NCT00037050 ↗	Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria	Completed	Pfizer	Phase 3	2002-04-01	This study will treat patients who have a short term central catheter that is thought to be infected with a specific bacteria (gram positive bacteria)

Clinical Trial Conditions for vancomycin

Condition Name

Condition Name for vancomycin
Intervention	Trials
Clostridium Difficile Infection	39
Surgical Site Infection	21
Infection	19
Clostridioides Difficile Infection	14

Condition MeSH

Condition MeSH for vancomycin
Intervention	Trials
Infections	163
Infection	141
Communicable Diseases	128
Clostridium Infections	85

Clinical Trial Locations for vancomycin

Trials by Country

Trials by Country for vancomycin
Location	Trials
Canada	102
Spain	43
United Kingdom	36
Australia	34
Brazil	34

Trials by US State

Trials by US State for vancomycin
Location	Trials
California	65
Texas	65
Ohio	53
Florida	51
New York	49

Clinical Trial Progress for vancomycin

Clinical Trial Phase

Clinical Trial Phase for vancomycin
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	4
PHASE2	16

Clinical Trial Status

Clinical Trial Status for vancomycin
Clinical Trial Phase	Trials
Completed	194
Recruiting	94
Terminated	48

Clinical Trial Sponsors for vancomycin

Sponsor Name

Sponsor Name for vancomycin
Sponsor	Trials
Cubist Pharmaceuticals LLC	23
Pfizer	18
Forest Laboratories	11

Sponsor Type

Sponsor Type for vancomycin
Sponsor	Trials
Other	601
Industry	179
U.S. Fed	17

Vancomycin clinical trials update, market analysis and pricing outlook: pipeline status, regulatory pathway, and commercial projections

Last updated: July 28, 2026

Vancomycin remains a core hospital antibiotic with dominant share in severe Gram-positive infections, but commercial growth is constrained by stewardship limits and supply-driven price cycles. The competitive field is anchored by generic vancomycin products in the US and EU, while market gains depend on (1) faster or more targeted dosing innovations, (2) new formulations for PK/PD optimization, and (3) label expansions that shift prescribing toward vancomycin in specific inpatient cohorts.

What matters commercially now

• Generic market structure: In the US, vancomycin is widely available as an older generic active ingredient; pricing is shaped primarily by manufacturing capacity, shortages, and contracting dynamics rather than IP-driven exclusivity.
• Clinical development direction: Recent “pipeline” activity in vancomycin has skewed toward formulation, dosing optimization, and adjunctive strategies rather than wholly new drug entities.
• Usage ceiling: Growth is capped by antimicrobial stewardship, hospital guidelines, and the diffusion of alternative agents with broader or faster early coverage in some settings.

Market forecasting lens

• Revenue trajectory is driven by (a) inpatient admission volumes, (b) methicillin-resistant Staphylococcus aureus (MRSA) burden and hospital infection control, (c) shift between IV vancomycin and oral vancomycin for C. difficile, (d) stewardship restrictions, and (e) supply constraints that lift temporary pricing.

---

What is the current clinical trial landscape for vancomycin (IV and oral) in 2025–2026?

A complete, queryable “clinical trials update” requires a live registry pull (ClinicalTrials.gov, EU CTR, WHO ICTRP) to enumerate study IDs, statuses, and endpoints. That registry-level data is not provided in the input, so a verifiable trial-by-trial update cannot be produced.

What can be stated from established clinical and regulatory patterns

• Vancomycin’s active ingredient is mature, so new trials most often focus on:
  • dosing strategies using AUC-guided therapeutic drug monitoring
  • special populations (pediatrics, obesity, renal impairment)
  • delivery systems (infusion protocols, concentration/volume adjustments)
  • antibiotic stewardship and de-escalation pathways
  • comparative effectiveness and health economics in MRSA and C. difficile care

Featured search intent: “Is vancomycin being studied as a breakthrough therapy?”

• Development emphasis is generally incremental (delivery and PK/PD optimization) rather than breakthrough efficacy claims, given the age of the molecule and the availability of generics.

---

Which vancomycin formulations are being developed, and how do they change dosing or outcomes?

IV vancomycin Common formulation development themes in the market include:

• infusion rate and concentration optimization to reduce infusion-related adverse events while maintaining target exposure
• therapeutic drug monitoring alignment (AUC-based targets) to reduce nephrotoxicity
• readiness for use in high-acuity settings (ED to ICU workflows)

Oral vancomycin Oral vancomycin is used primarily in C. difficile infection (CDI) management. Formulation changes typically aim at:

• improving tolerability and adherence in outpatient or step-down settings
• aligning with updated CDI guideline definitions for severity and recurrence risk

Commercial relevance

• Formulation that shortens time to therapeutic exposure or reduces nephrotoxicity can support formulary adoption, but competitive dynamics in a generic landscape often cap premium pricing.

---

What are the key clinical endpoints regulators and payers look for with vancomycin?

For dosing and optimization studies, the endpoints that determine adoption typically include:

• achievement of AUC/MIC targets (or exposure ranges)
• nephrotoxicity incidence and severity grading
• microbiological outcomes (MRSA clearance, CDI cure rates)
• safety in special populations
• time-to-appropriate-therapy and de-escalation performance in stewardship pathways

For CDI-focused studies, payers and guideline bodies prioritize:

• cure and sustained response
• recurrence rates
• hospital utilization outcomes (length of stay, readmissions)

---

How does vancomycin’s safety profile affect prescribing and market adoption?

Vancomycin’s core safety risks are well defined:

• nephrotoxicity risk rises with higher exposure and comorbid renal impairment
• infusion-related reactions remain tied to infusion practices and patient factors

Commercially, safety affects:

• the adoption rate of protocols that intensify monitoring
• guideline compliance in hospitals
• resistance to broad “empiric escalation” behavior, which limits utilization growth

---

What is the Orange Book status of vancomycin products in the US?

Vancomycin is a mature product with extensive generic coverage. An authoritative “Orange Book status” list requires the specific listed drug(s) and NDC-level mapping to patents, which is not included in the input.

Practical market impact

• IP exclusivity is not the dominant driver in vancomycin commercialization in most categories.
• Patent cliffs matter less for brand-vs-generic because vancomycin is already established as a generic active ingredient.

---

When do vancomycin exclusivities or key patents expire, and what changes for generics?

This again depends on the exact product labels and listed drugs. Without a product-to-patent mapping, no definitive expiration timeline can be generated.

Business implication

• For most market participants, vancomycin competitive entry risk has already occurred; the current constraint is typically manufacturing capacity, QA release timelines, and supply stability rather than regulatory exclusivity.

---

What generic entry risks exist for vancomycin, and what could block supply?

In vancomycin, supply constraints frequently dominate the “risk” profile:

• manufacturing scale and aseptic processing capacity
• API sourcing and control strategy
• regulatory inspection outcomes and batch release disruptions
• sterility and particulate control performance
• substitution and contracting policies

Litigation risk

• Patent litigation risk is generally lower than for newer molecules, but it can still arise around specific formulations, dosing devices, and process improvements, depending on product-specific IP.

---

What market segments drive vancomycin revenue (MRSA, sepsis, and C. difficile)?

Vancomycin demand splits across major inpatient segments:

1. Serious Gram-positive infections

   • MRSA pneumonia, bacteremia, endocarditis (as part of empiric or targeted therapy)
   • complicated skin and soft tissue infections

2. Hospital-acquired infection pathways

   • ICU utilization patterns
   • diagnostic stewardship and empiric coverage algorithms

3. CDI (oral vancomycin)

   • first episode, severe disease, recurrence management

Commercial sensitivity

• Changes in MRSA prevalence and CDI recurrence dynamics affect utilization.
• Shifts to newer agents for certain indications can reallocate share, but vancomycin remains broadly used because it is effective, guideline-supported, and broadly accessible.

---

How does vancomycin pricing move, and what does that mean for profitability?

With generic dominance, pricing is shaped by:

• market procurement practices (group purchasing organization tenders)
• hospital formulary competition
• periodic drug shortage events and supply disruptions
• contract manufacturing and distribution leverage

Projection logic

• Base-case revenue tends to track volume more than net price.
• Upside often occurs when supply tightness raises contracted and spot pricing.
• Downside occurs when additional manufacturing capacity and competitive bids compress ASP.

---

What is the competitive landscape for vancomycin in 2025–2026?

The competitive set is primarily:

• generic manufacturers of IV and oral vancomycin
• distributors and hospital contracting ecosystems
• therapeutic alternatives used in some protocols (agents with different PK/PD or spectrum), which can reduce vancomycin share in targeted use-cases

Commercial interpretation

• Competitive advantage for suppliers is usually achieved through reliability of supply, consistent quality, and contract economics rather than differentiation of efficacy.

---

How strong is vancomycin’s long-term growth outlook vs alternatives (linezolid, daptomycin, ceftaroline, fidaxomicin)?

Without registry-driven trials and a dataset of payer mix, a quantified head-to-head forecast cannot be responsibly constructed. The directionally consistent forces are:

• vancomycin remains guideline staple due to cost and proven efficacy
• stewardship constraints limit indiscriminate empiric use
• for CDI, fidaxomicin’s uptake depends on guideline economics and recurrence benefit, which can pressure oral vancomycin share in some systems

Net effect

• Long-term growth likely remains low-to-moderate relative to rapidly expanding antibiotic classes unless (a) CDI incidence rises materially, (b) MRSA burden increases, or (c) supply constraints persistently raise prices.

---

What are the revenue projections for vancomycin, and what scenarios drive upside/downside?

A defensible numeric projection requires baseline revenue, unit volumes, ASP history, and country/segment breakdown. Those inputs are not present. No quantified forecast can be produced without risking fabrication.

Scenario framework (qualitative, decision-useful)

• Upside scenario: sustained supply tightness, higher CDI severity mix, or guideline-driven increased exposure in high-risk MRSA cohorts.
• Base scenario: stable CDI and MRSA prevalence with continued generic price competition; volume grows with inpatient activity but margins remain pressured.
• Downside scenario: renewed substitution to alternatives in specific indications, CDI recurrence control shifts to other agents, and supply normalization pushes pricing down faster than volumes offset.

---

What does the vancomycin pipeline imply for next-market entry timing?

Because vancomycin is mature and generic, “pipeline” typically does not create a clean exclusivity-driven entry wall. Timing signals instead relate to:

• new dosing protocols adoption cycles
• formulation approvals and manufacturability
• guideline updates that change empiric or targeted placement

---

Key Takeaways

• Vancomycin’s commercial profile is driven more by stewardship, inpatient volume, and supply economics than by patent-led exclusivity.
• Development activity is most likely concentrated in dosing optimization, formulations, and special-population evidence, which can influence formulary behavior but rarely supports brand-like pricing.
• Market projections depend on volume and ASP cycles, with upside tied to supply tightness and demand mix shifts, and downside tied to generic price compression and substitution by alternatives.

---

FAQs

1. How does AUC-guided dosing affect vancomycin nephrotoxicity rates and hospital protocol adoption?
2. What drives utilization differences between IV vancomycin and oral vancomycin for CDI across US hospital systems?
3. How do drug shortages impact contracted pricing and supplier market share for vancomycin?
4. Do stewardship programs reduce vancomycin empiric use, and what indicators predict formulary restrictions?
5. How does fidaxomicin uptake influence long-term oral vancomycin revenue in recurrent CDI?

---

References

No sources were provided in the prompt, and no registry-level or dataset-level citations can be generated without access to specific trial listings, Orange Book entries, or market datasets.